
Novo Nordisk shares fell sharply on Wednesday after the company warned that sales and profits will drop in 2026.
The Danish drugmaker’s stock slid about 17% in early trading in Copenhagen, erasing gains made earlier in the year. The fall followed an unexpected pre-release of the company’s outlook for 2026.